Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Macy's Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.6 (market cap $30.93B), while Macy's Inc trades at $22.62 (market cap $5.92B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 5.2× Macy's Inc's market cap, and Macy's Inc pays the higher dividend (3.38%). Which is the better fit depends on your goals.
| GEHC | M | |
|---|---|---|
Market Cap | $30.93B | $5.92B |
Volume | 5,033,451 | 7,798,987 |
Sector | Health | Consumer Cyclical |
52-Week High | $88.16 | $26.21 |
52-Week Low | $59.48 | $16.92 |
Enterprise Value | $39.39B | $9.72B |
Dividend Yield | 0.23% | 3.38% |
Typical Hold Time | — | 58 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Macy's (M) trades at $22.74, down 1.09% on the day, with a bullish technical signal from moving averages. The stock shows attractive valuation with a P/E of 8.33 and P/S of 0.27. Recent earnings have consistently beaten estimates, and the company's 'A Bold New Chapter' strategy is driving digital and omnichannel growth, supporting a raised 2026 outlook despite near-term investment pressures.
The outlook is cautiously optimistic, with upside to the $24.25 consensus price target. Investment opportunities include a sustainable dividend yield and undervaluation relative to peers. Key risks are soft second-half comps, margin pressure from tariffs, and intense retail competition. Execution of the turnaround strategy remains critical for sustained shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
